E. coli O157:H7 C1-INH-binding protein and methods of use

Details E. coli O157:H7 C1-INH-binding protein and methods of use E. coli O157:H7 C1-INH-binding protein and methods of use

2007-05-08

2007-05-08

Saidha, Tekchand (Department: 1652)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

C435S212000, C435S069100, C536S023200

Reexamination Certificate

active

10786445

ABSTRACT:
Disclosed is a pO157 plasmid-specified polypeptide found inE. coliEDL933 and otherE. colithat binds to and cleaves C1-esterase inhibitor, and antibodies specific for the polypeptide. Also disclosed are methods employing the polypeptide for diagnosing enterohemorrhagicE. coliinfection, identifying potential inhibitors of its activity, and reducing viscosity of material containing glycosylated polypeptides.

REFERENCES:
patent: 6872559 (2005-03-01), Welch et al.
patent: 2006/0153828 (2006-07-01), Welch et al.
patent: WO 02/34918 (2002-05-01), None
Bauer, M. E. & Welch, R. A. (1996) “Characterization of an RTX Toxin from EnterohemorrhagicEscherichia coliO157:H”Infect. Immun. 64(1):167-175.
Bergamaschini, L., G. Gobbo, S. Gatti, L. Caccamo, P. Prato, M. Maggioni, P. Braidotti, R. Di Stefano, and L.R. Fassati. (2001) “Endothelial targeting with C1-inhibitor reduces complement activation in vitro and during ex vivo reperfusion of pig liver”Clin Exp Immunol126:412-420.
Berggard, K., E. Johnsson, E. Morfeldt, J. Persson, M. Stalhammar-Carlemalm, and G. Lindahl. (2001) Binding of human C4BP to the hypervariable region of M protein: a molecular mechanism of phagocytosis resistance in Streptococcus pyogenes.Mol Microbiol42(2):539-551.
Boucher, R.C. (2002) “An overview of the pathogenisis of cystic fibrosis lung disease”Advanced Drug Delivery Reviews, 54:1359-1371.
Burland, V., Shao, Y., and Perna, N. T., Plunkett, G., Sofia, H. J. & Blattner, F. R. (1998) “The complete DNA sequence and analysis of the large virulance plasmid ofEscherichia coliO157:H7”Nucleic Acids Research26(18):4196-4204.
Burland, V., Shao, Y., Perna, N. T., Plunkett, G., Sofia, H. J. & Blattner, F. R. Accession T42131; T00210 (Dec. 3, 1999 # Sequence—revision; Dec. 3, 1999 # text—change Nov. 17, 2002)Nucleic Acids Research26:4196-4204.
Cai, S., and A.E. Davis, 3rd. (2003) “Complement regulatory protein C1 inhibitor binds to selectins and interferes with endothelial-leukocyte adhesion”J Immunol171:4786-4791.
Caldwell, E.E., A.M. Andreasen, M.A. Blietz, J.N. Serrahn, V. VanderNoot, Y. Park, G. Yu, R.J. Linhardt, and J.M. Weiler. (1999) “Heparin binding and augmentation of C1 inhibitor activity”Arch Biochem Biophys361:215-222.
Caliezi, C., Wuillemin, W. A., Zeerleder, S., Redondo, M., Eisele, B. & Hack, C. E. (2000) C1-Esterase Inhibitor: An Anti-Inflammatory Agent and Its Potential Use in the Treatment of Diseases Other than Heredityary AngioedemaPharmacol. Rev. 52(1):91-112.
Caprioli, A., Luzzi, I., Gianviti, A., Russmann, H. & Karch, H. (1995) “Pheno-genotyping of verotoxin 2 (VT2)-producingEscherichia colicausing haemorrhagic colitis and haemolytic uraemic syndrom by direct analysis of patients' stools” J.Med. Microbiol. 43:348-353.
Catanese, J. & Kress, L. F. (1984) “Enzymatic Inactivation of Human Plasma C1-Inhibitor and a1- Antichymotrypsin byPseudomonas aeruginosaproteinase and Elastase”Biochim. Biophys. Acta789:37-43.
Chan, J.Y., C.E. Burrowes, F.M. Habal, and H.Z. Movat. (1977) “The inhibition of activated factor XII (Hageman factor) by antithrombin III: the effect of other plasma proteinase inhibitors”Biochim Biophys Res Commun74:150-158.
Cooper, N.R. (1991) “Complement evasion strategies of microorganisms”Immunol Today12:327-331.
Coutinho, M., K.S. Aulak, and A.E. Davis. (1994) “Functional analysis of the serpin domain of C1 inhibitor”J Immunol153:3648-3654.
Datsenko and Warner (2000) “One-step inactivation of chromosomal genes inEscherichia coliK-12 using PCR products” PNAS 97(12) 6640-6645.
de Agostini, A., M. Schapira, Y.T. Wachtfogel, R.W. Colman, and S. Carrel. (1985) “Human plasma kallikrein and C1 inhibitor form a complex possessing an epitope that is not detectable on the parent molecules: demonstration using a monoclonal antibody”Proc Natl Acad Sci U S A82:5190-5193.
Dean-Nystrom, E, et al. (2002) “Vaccination of Pregnant Dams with IntiminO157Protects Suckling Piglets fromEscherichia coliO157:H7 Infection”Infection and Immunity. 70(5):2414-2418.
DeLoney, et al. (2002) “Role for Phosphoglucomutase inVibrio fischeri-Euprymna scolposeSymbiosis”J. Bacteriology, 184(18):5121-5129.
DeLorenzo, V. D. & Timmis, K. N. (1994) “Analysis and Construction of Stable Phenotypes in Gram-Negative Bacteria with Tn5-and Tn10- Derived Minitransposons”Bacterial Pathogenesis, eds. Clark, V: L. & Bavoil, P. M. (Academic Press, San Diego), 235:386-405.
Donnenberg, M.S. & Nataro, J.P. (1992) “Methods for Studying Adhesion of DiarrheagenicEscherichia coli” Methods in Enzymology, 253:324-327.
Elson, C. & Ealding, W. (1984) “Generalized Systemic and Mucosal Immunity in Mice after Mucosal Stimulation with Cholera Toxin”Journal of Immunology, 132(6):2736-2741.
Elson, C. & Ealding, W. (1984) “Cholera Toxin Feeding did not Induce Oral Tolerance in Mice and Abrogated Oral Tolerance to an Unrelated Protein”Journal of Immunology, 133(6):2892-2897.
Eriksson, K., et al. (2003) “Cholera Toxin and Its B Subunit Promote Dendritic Celll Vaccination with Different Influences on Th1 and Th2 Development”Infection and Immunity, 71(4):1740-1747.
Frank, M.M. (1992) “The mechanism by which microorganisms avoid complement attack”Curr Opin Immunol4:14-19.
Frank, M.M., and L.F. Fries. (1989) “Complement. In Fundamental Immunology” W.E. Paul, editor. Raven Press, New York.
Frankel, G., A.D. Phillips, I. Rosenshine, G. Dougan, J.B. Kaper, and S. Knutton. (1998) “Enteropathogenic and enterohaemorrhagicEscherichia coli: more subversive elements”Mol Microbiol30(5):911-921.
Gadek, J. E., Hosea, S. W., Gelfand, J. A., Santaella, M., Wickerhauser, M., Triantaphyllopoulos, D. C. & Frank, M. M. (1980) “Replacement Therapy in Hereditary Angioedema”N. Engl. J. Med. 302(10):542-546.
Gigli, I., T. Fujita, and V. Nussenzweig. (1979) “Modulation of the classical pathway C3 convertase by plasma proteins C4 binding protein and C3b inactivator”Proc Natl Acad Sci U S A76:6596-6600.
Harlow, E., and D. Lane. (1988) Antibodies: a laboratory manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor.
Hauert, J., P.A. Patston, and M. Schapira. (2000) “C1 inhibitor cross-linking by tissue transglutaminase”J Biol Chem275(19):14558-14562.
Hellwage, J., T. Meri, T. Heikkila, A. Alitalo, J. Panelius, P. Lahdenne, I.J. Seppala, and S. Meri. (2001) “The complement regulator factor H binds to the surface protein OspE ofBorrelia burgdorferi*” J Biol Chem276(11):8427-8435.
Hong, Y.Q., and B. Ghebrehiwet. (1992) “Effect ofPseudomonas aeruginosaelastase and alkaline protease on serum complement and isolated components C1q and C3”Clin Immunol Immunopathol62:133-138.
Huntington, J.A., R.J. Read, and R.W. Carrell. (2000) “Structure of a serpin-protease complex shows inhibition by deformation”Nature407:923-926.
Jiang, H., E. Wagner, H. Zhang, and M.M. Frank. (2001) “Complement 1 Inhibitor is a regulator of the alternative complement pathway”J Exp Med194:1609-1616.
Jiang, W. & Bond, J. S. (1992) “Families of metalloendopeptidases and their relationship”FEBS Lett312(2,3):110-114.
Judge, N., et al. (2004) “Plant Cell-Based Intimin Vaccine Given Orally to Mice Primed with Intimin Reduces Time ofEscherichia coliO157:H7 Shedding in Feces”Infection and Immunity, 72(1):168-175.
Jung, C.-M., Matsushita, O., Katayama, S., Minami, J., Sakurai, J. & Okabe, A. (1999) “Identification of Metal Ligands in theClostidium histolyticumCohH Collagenase”J. Bact. 181(9):2816-2822.
Karmali, M. A., Petric, M., Steele, B. T. & Lim, C. (1983) “Sporadic Cases of Haemolytic-Uraemic Syndrom Associated with Faecal Cytotoxin and Cytotoxin-ProducingEscherichia coliin Stool

Affiliated with

Also associated with

Rating

E. coli O157:H7 C1-INH-binding protein and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with E. coli O157:H7 C1-INH-binding protein and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and E. coli O157:H7 C1-INH-binding protein and methods of use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3763105